Abstract

BackgroundPrevious studies reported that patients with preexisting radiological interstitial lung abnormalities (ILAs) were more susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy (TRT). The present study aimed to evaluate the incidence and predictors of RP after TRT in patients with small-cell lung cancer (SCLC) with or without preexisting radiological ILAs.MethodsA total of 95 consecutive patients with SCLC between January 2015 and December 2015, who were treated with thoracic intensity-modulated radiation therapy at Shanghai Pulmonary Hospital,Tongji University School of Medicine, were analyzed. The diagnosis of ILAs was reviewed by two experienced thoracic radiologists based on the pretreatment high-resolution computed tomography imaging, such as honeycombing, subpleural reticular opacities, ground-glass opacity, and traction bronchiectasis. Univariate and multivariate analyses were used to assess the correlation of clinical factors, preexisting radiological ILAs, and dose-volume histogram-based dosimetric parameters with RP.ResultsFifteen (15.8%) patients had preexisting radiological ILAs. The incidence of ≥ grade 2 and 3 RP at 1 year was 27.1% and 12.7% in the entire cohort, respectively. Preexisting radiological ILAs were associated with an increased risk of ≥grade 2 RP (50.0% in ILAs + vs 23.3% in ILAs−, P = 0.017) and ≥ grade 3 RP (35.8% in ILAs + vs 8.9% in ILAs−, P = 0.005) at 1 year. Preexisting radiological ILAs and smoking history (≥40 pack-years of smoking) were significant predictors of ≥grade 3 RP in multivariate analysis (P = 0.023 and 0.012, respectively).ConclusionsPreexisting radiological ILAs and smoking history (≥40 pack-years of smoking) are associated with an increased risk of ≥grade 3 RP after TRT in patients with SCLC.

Highlights

  • Previous studies reported that patients with preexisting radiological interstitial lung abnormalities (ILAs) were more susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy (TRT)

  • Symptomatic radiation pneumonitis (RP) is a major complication occurring in 15%–40% of the patients with lung cancer receiving concurrent chemoradiotherapy [5]

  • Previous studies demonstrated that the dose-volume parameters, such as V20, V5, mean lung dose (MLD), treatment factors, tumor factors, and patient factors, are predictors for developing clinically evident radiation pneumonitis

Read more

Summary

Introduction

Previous studies reported that patients with preexisting radiological interstitial lung abnormalities (ILAs) were more susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy (TRT). Previous studies demonstrated that the dose-volume parameters, such as V20 (percentage of the lung volume receiving ≥20 Gy), V5 (percentage of the lung volume receiving ≥5Gy), mean lung dose (MLD), treatment factors (e.g., sequential/concurrent chemotherapy schedules), tumor factors (e.g., disease location in the lower lung, tumor size), and patient factors (e.g., smoking history, presence of comorbidity), are predictors for developing clinically evident (grades 2–3) radiation pneumonitis. These factors were correlated with RP in patients with lung cancer [5,6,7,8,9,10,11,12]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call